Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
News ID: 142 Publish Date : 2026/05/13
Health
ECONEWS – The second exhibition on Iran's advanced technologies in Persian medicine (known as Farre Iran) will be held to introduce the country’s technological and knowledge-based products.
News ID: 115 Publish Date : 2026/05/11
China
ECONEWS – Since arriving in Iran, I have met many young Iranians. Their passion and energy have left a deep impression on me. Iranian friends are also very interested in what the younger generation in China looks like. China's Youth Day has just passed. Originating 107 years ago as a patriotic student movement, the day now serves as a window into the lives of young Chinese people today. Who are they? What concerns them? How are they engaging with society? I would like to share a few observations with our Iranian friends.
News ID: 114 Publish Date : 2026/05/11
China
ECONEWS – Since arriving in Iran, I have met many young Iranians. Their passion and energy have left a deep impression on me. Iranian friends are also very interested in what the younger generation in China looks like. China's Youth Day has just passed. Originating 107 years ago as a patriotic student movement, the day now serves as a window into the lives of young Chinese people today. Who are they? What concerns them? How are they engaging with society? I would like to share a few observations with our Iranian friends.
News ID: 114 Publish Date : 2026/05/11
